638 related articles for article (PubMed ID: 28987463)
1. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic approaches in Parkinson's disease and related disorders.
Valera E; Masliah E
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
[TBL] [Abstract][Full Text] [Related]
3. Active immunization therapies for Parkinson's disease and multiple system atrophy.
Schneeberger A; Tierney L; Mandler M
Mov Disord; 2016 Feb; 31(2):214-24. PubMed ID: 26260853
[TBL] [Abstract][Full Text] [Related]
4. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
Knecht L; Folke J; Dodel R; Ross JA; Albus A
Neurotherapeutics; 2022 Sep; 19(5):1489-1502. PubMed ID: 36083395
[TBL] [Abstract][Full Text] [Related]
7. Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.
Upcott M; Chaprov KD; Buchman VL
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885933
[TBL] [Abstract][Full Text] [Related]
8. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
9. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
Peelaerts W; Baekelandt V
J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
[TBL] [Abstract][Full Text] [Related]
10. Development of Passive Immunotherapies for Synucleinopathies.
Bergström AL; Kallunki P; Fog K
Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
13. Potential Modes of Intercellular α-Synuclein Transmission.
Valdinocci D; Radford RA; Siow SM; Chung RS; Pountney DL
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241427
[TBL] [Abstract][Full Text] [Related]
14. Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera E; Masliah E
Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
Visanji NP; Brotchie JM; Kalia LV; Koprich JB; Tandon A; Watts JC; Lang AE
Trends Neurosci; 2016 Nov; 39(11):750-762. PubMed ID: 27776749
[TBL] [Abstract][Full Text] [Related]
17. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
Fernagut PO; Dehay B; Maillard A; Bezard E; Perez P; Pavy-Le Traon A; Rascol O; Foubert-Samier A; Tison F; Meissner WG
Neurobiol Dis; 2014 Jul; 67():133-9. PubMed ID: 24727096
[TBL] [Abstract][Full Text] [Related]
18. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
19. Prying into the Prion Hypothesis for Parkinson's Disease.
Brundin P; Melki R
J Neurosci; 2017 Oct; 37(41):9808-9818. PubMed ID: 29021298
[TBL] [Abstract][Full Text] [Related]
20. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
Vekrellis K; Stefanis L
Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
